SlideShare uma empresa Scribd logo
1 de 23
BY-
AAYUSHI RAMBIA
M.Sc. SEM I
REG NO. 18308001
PONDICHERRY UNIVERSITY
 A vaccine is a biological preparation that improves
immunity to a particular disease. A vaccine typically
contains an agent that resembles a disease-causing
microorganism, and is often made from weakened or
killed forms of the microbe, its toxins or one of its surface
proteins. The agent stimulates the body's immune
system to recognize the agent as foreign, destroy it, and
"remember" it, so that the immune system can more
easily recognize and destroy any of these
microorganisms that it later encounters.
(Definition as adopted from WHO)
1796
• British physician , Edward Jenner used the cowpox virus (vaccinia) to confer protection
against smallpox, a related virus, in humans.
1870
1885
• Louis Pasteur created the first live attenuated bacterial vaccine against chicken cholera.
• He created the first live attenuated viral vaccine against rabies.
1890-
1904
• Von Behring and Kitasato Shibasaburo successfully tested vaccines for diphtheria and
tetanus
1914
• Tetanus vaccine becomes available.
1920-
1940
• Vaccines against tuberculosis , diphtheria and yellow fever , influenza and whooping cough
created.
1955-
1960
• Salk and Sabin created two different types of vaccines against polio myelitis.
(Adapted from Nature Reviews
Microbiology volume9, pages889–893 (2011)
 Recombinant DNA vaccines or simply DNA vaccines are
plasmid containing the DNA sequence encoding the
antigen(s) against which an immune response is sought,
and relies on the in situ production of the target antigen.
 Upon the injection of the DNA vaccines , the DNA is
taken up by the cells and the encoded protein antigen is
expressed , leading to both a humoral anitbody response
and a cell mediated immune response.
 These belong to the third generation of vaccines .
 The use of DNA as a vaccine started with the work of Jon
Wolff who injected DNA plasmids to produce a protein
response in mice.
(Adapted from
www.mdpi.com/journal/vaccines/special_issues/DNA-
vaccines)
 DNA vaccines are composed of bacterial plasmids.
 Expression plasmids used in DNA-based vaccination
normally contain two units:
1) The antigen expression unit composed of
promoter/enhancer sequences, followed by antigen-
encoding and polyadenylation sequences and
2) the production unit composed of bacterial sequences
necessary for plasmid amplification and selection .
 The construction of bacterial plasmids with vaccine
inserts is accomplished using recombinant DNA
technology.
 Once constructed, the vaccine plasmid is transformed
into bacteria, where bacterial growth produces multiple
plasmid copies.
 The plasmid DNA is then purified from the bacteria, by
separating the circular plasmid from the much larger
bacterial DNA and other bacterial impurities.
 This purified DNA acts as the vaccine.
ANTIGENIC GENE
PLASMID VECTOR
RECOMBINANT VECTOR
STEPS THEREAFTER
(ADAPTED FROM NPTEL)
 The major approaches involved in administration of DNA
vaccines are :-
1) Injection of DNA vaccine in saline, using a standard
hypodermic needle. Injection in saline is normally
conducted intramuscularly (IM) in skeletal muscle,
or intradermally (ID), delivering DNA to extracellular
spaces. This can be assisted by electroporation by
temporarily damaging muscle fibres with myotoxins
such as bupivacaine; or by using hypertonic solutions of
saline or sucrose.
Through this method large amounts of DNA
approximately 100-200 µg can be delivered .
2) Gene gun method involves the injection of plasmid DNA
(pDNA) that has been adsorbed onto gold or tungsten
micro particles into the target cells using compressed
helium as an accelerant.
Usually administered to ED (abdominal skin) , vaginal
mucosa or surgically exposed muscle and other organs.
Through this method small amounts of DNA
approximately 16 ng can be delivered.
The method sometimes causes burning sensation and in
order to avoid this nowadays low pressure gene guns are
used instead of gold coated DNA vaccines.
3) Another method includes the administration through
pneumatic jet injections ED (abdominal skin). It helps
deliver large amounts approximately 300 µg .
4) Aerosol instillation of naked DNA
on mucosal surfaces, such as the nasal and lung mucosa
and topical administration of pDNA to the eye. It helps
deliver small amounts of DNA approximately upto 100
µg.
 By two major pathways :-
1)Endogenous
Antigenic Protein is presented by cell in which it is
produced
Antigenic
Protein
Antigenic
Peptides
Plasmid
DNA
Nucleus
mRNA
MHC-I
Helper T-cell
Memory T- cells
Plasma T-cell
2) Exogenous
Antigenic Protein is formed in one cell but presented by
different cell.
Antigenic Protein come
outside
Antigen Presenting Cell
Antigenic Peptides
T- Helper Cell
Cytokines
Activated B-Cell
Memory B-Cell
Plasma B-Cell
Memory
Antibodies
MHC-II
 Vaccination with no risk for infection.
 Antigen presentation by both MHC class I and class II
molecules.
 Immune response focused only on antigen of interest.
 Stability of vaccine for storage and shipping
 Cost-effectiveness.
 Long-term persistence of immunogen
ADVANTAGES OF DNA VACCINES
 Limited to protein immunogens
 Risk of affecting genes controlling cell growth
 Possibility of inducing antibody production against DNA
 Possibility of tolerance to the antigen (protein) produced
 Plasmid used is resistance to antibiotics for selection. It
may raise the resistance to same antibiotic in the host
 Over – expression may cause acute inflamatory
response.
There are currently 43 clinical trials evaluating DNA
vaccines for viral and non-viral diseases listed in
the clinicaltrials.gov database. The majority (62%) of
these trials are investigating vaccines for HIV (33%) or
cancers (29%). Almost half (38%) of cancer vaccines
currently being investigated are targeting melanoma. The
remaining 38% of enrolling or active clinical trials are
investigating vaccines for influenza, hepatitis B and C,
HPV, and malaria.
From: Clinical Applications of DNA Vaccines: Current Progress . Published
by Oxford University Press on behalf of the Infectious Diseases Society of
America
 With the advent of DNA vaccines there came a possibility for
treatment of incurable diseases such HIV ,Hepatitis and
Cancer.
 Despite remarkable progress in the field of DNA vaccine
research since its discovery in the early 1990s, the formal
acceptance of this novel technology as a new modality of
human vaccines depends on the successful demonstration of
its safety and efficacy in advanced clinical trials.
 Although clinical trials conducted so far have provided
overwhelming evidence that DNA vaccines are well tolerated
and have an excellent safety profile, the early designs of DNA
vaccines failed to demonstrate sufficient immunogenicity in
humans. However, studies conducted over the last few years
have led to promising results, particularly when DNA vaccines
were used in combination with other forms of vaccines.
 Immunology by Kuby 4th Edition
 Immunology by Kuby 6th Edition
 Tang DC, DeVit M, Johnston SA. (1992)“Genetic
immunization is a
simple method for eliciting an immune response”.
Nature; 356:152-4
 https://www.tandfonline.com/doi/full/10.1586/14760584.7.
2.175
 Clinical Infectious Diseases, Volume 53, Issue 3, 1
August 2011, Pages 296–
302,https://doi.org/10.1093/cid/cir334
 www.nptel.com
 https://www.nature.com/articles/nrg2432
 https://www.nature.com/articles/gt201467
 Google images

Mais conteúdo relacionado

Mais procurados

SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINE
SYNTHETIC PEPTIDE  VACCINES  AND RECOMBINANT  ANTIGEN VACCINESYNTHETIC PEPTIDE  VACCINES  AND RECOMBINANT  ANTIGEN VACCINE
SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINE
D.R. Chandravanshi
 
Subunit and peptide vaccine
Subunit and peptide vaccineSubunit and peptide vaccine
Subunit and peptide vaccine
Adnya Desai
 

Mais procurados (20)

SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINE
SYNTHETIC PEPTIDE  VACCINES  AND RECOMBINANT  ANTIGEN VACCINESYNTHETIC PEPTIDE  VACCINES  AND RECOMBINANT  ANTIGEN VACCINE
SYNTHETIC PEPTIDE VACCINES AND RECOMBINANT ANTIGEN VACCINE
 
Recombinant vaccines
Recombinant vaccinesRecombinant vaccines
Recombinant vaccines
 
Recombinant vaccines
Recombinant vaccinesRecombinant vaccines
Recombinant vaccines
 
DNA Vaccine
DNA VaccineDNA Vaccine
DNA Vaccine
 
Synthetic peptide vaccines.pptx
Synthetic peptide vaccines.pptxSynthetic peptide vaccines.pptx
Synthetic peptide vaccines.pptx
 
Adjuvants
AdjuvantsAdjuvants
Adjuvants
 
DNA vacccine
DNA vacccine DNA vacccine
DNA vacccine
 
New generation vaccines production
New generation vaccines productionNew generation vaccines production
New generation vaccines production
 
Vaccines
VaccinesVaccines
Vaccines
 
Retroviral Vectors
Retroviral VectorsRetroviral Vectors
Retroviral Vectors
 
Subunit and peptide vaccine
Subunit and peptide vaccineSubunit and peptide vaccine
Subunit and peptide vaccine
 
M13 and Mu Virus Structure and Life Cycle
M13 and Mu Virus Structure and Life CycleM13 and Mu Virus Structure and Life Cycle
M13 and Mu Virus Structure and Life Cycle
 
Immunotoxins
ImmunotoxinsImmunotoxins
Immunotoxins
 
Antibody class switch ppt
Antibody class switch pptAntibody class switch ppt
Antibody class switch ppt
 
New generation vaccines
New generation vaccinesNew generation vaccines
New generation vaccines
 
DNA Vaccine.pptx
DNA Vaccine.pptxDNA Vaccine.pptx
DNA Vaccine.pptx
 
mRNA VACCINES.pptx
mRNA VACCINES.pptxmRNA VACCINES.pptx
mRNA VACCINES.pptx
 
Vaccine and adjuvants
Vaccine and adjuvantsVaccine and adjuvants
Vaccine and adjuvants
 
Recombinant vaccine
Recombinant vaccineRecombinant vaccine
Recombinant vaccine
 
Sv 40
Sv 40Sv 40
Sv 40
 

Semelhante a DNA Vaccines

Presentation on conventional vaccine (Quality Control and Production aspects)
Presentation on conventional vaccine (Quality Control and Production aspects)Presentation on conventional vaccine (Quality Control and Production aspects)
Presentation on conventional vaccine (Quality Control and Production aspects)
Sunny Rathee
 
De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009
Annie De Groot
 

Semelhante a DNA Vaccines (20)

Recent advances in Vaccine_Dr. Mansij Biswas
Recent advances in Vaccine_Dr. Mansij BiswasRecent advances in Vaccine_Dr. Mansij Biswas
Recent advances in Vaccine_Dr. Mansij Biswas
 
Vaccines
VaccinesVaccines
Vaccines
 
Emerging trend in_biotechnology: Recombinant Vaccine technology
Emerging trend in_biotechnology: Recombinant Vaccine technologyEmerging trend in_biotechnology: Recombinant Vaccine technology
Emerging trend in_biotechnology: Recombinant Vaccine technology
 
R dna seminar
R dna seminarR dna seminar
R dna seminar
 
Presentation on conventional vaccine (Quality Control and Production aspects)
Presentation on conventional vaccine (Quality Control and Production aspects)Presentation on conventional vaccine (Quality Control and Production aspects)
Presentation on conventional vaccine (Quality Control and Production aspects)
 
Nisha revrse vaccinology
Nisha revrse vaccinology Nisha revrse vaccinology
Nisha revrse vaccinology
 
Vaccines
VaccinesVaccines
Vaccines
 
Devoplment of safer vaccine
Devoplment of safer vaccineDevoplment of safer vaccine
Devoplment of safer vaccine
 
Covid 19
Covid 19Covid 19
Covid 19
 
Vaccine converted
Vaccine convertedVaccine converted
Vaccine converted
 
Biotechnology presentation
Biotechnology presentationBiotechnology presentation
Biotechnology presentation
 
De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009De Groot Nova Se Immunology Of Vaccines2009
De Groot Nova Se Immunology Of Vaccines2009
 
Coronavirus Pandemic Part III (C): Vaccines (rev01)
Coronavirus Pandemic Part III (C): Vaccines (rev01)Coronavirus Pandemic Part III (C): Vaccines (rev01)
Coronavirus Pandemic Part III (C): Vaccines (rev01)
 
Vaccine
VaccineVaccine
Vaccine
 
Vaccination
VaccinationVaccination
Vaccination
 
Vaccines herd immunity anti vaccine movt
Vaccines herd immunity anti vaccine movtVaccines herd immunity anti vaccine movt
Vaccines herd immunity anti vaccine movt
 
Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01
Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01
Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01
 
Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01
Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01
Vaccinesherdimmunityantivaccinemovt 150213065803-conversion-gate01
 
Vaccine_delivery_systems.pptx
Vaccine_delivery_systems.pptxVaccine_delivery_systems.pptx
Vaccine_delivery_systems.pptx
 
Genomic Vaccines
Genomic VaccinesGenomic Vaccines
Genomic Vaccines
 

Último

Bacterial Identification and Classifications
Bacterial Identification and ClassificationsBacterial Identification and Classifications
Bacterial Identification and Classifications
Areesha Ahmad
 
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdfPests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
PirithiRaju
 
Formation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disksFormation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disks
Sérgio Sacani
 
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune WaterworldsBiogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Sérgio Sacani
 
Seismic Method Estimate velocity from seismic data.pptx
Seismic Method Estimate velocity from seismic  data.pptxSeismic Method Estimate velocity from seismic  data.pptx
Seismic Method Estimate velocity from seismic data.pptx
AlMamun560346
 
dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...
dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...
dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...
dkNET
 
Conjugation, transduction and transformation
Conjugation, transduction and transformationConjugation, transduction and transformation
Conjugation, transduction and transformation
Areesha Ahmad
 
Module for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learningModule for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learning
levieagacer
 

Último (20)

GBSN - Microbiology (Unit 2)
GBSN - Microbiology (Unit 2)GBSN - Microbiology (Unit 2)
GBSN - Microbiology (Unit 2)
 
Bacterial Identification and Classifications
Bacterial Identification and ClassificationsBacterial Identification and Classifications
Bacterial Identification and Classifications
 
Vip profile Call Girls In Lonavala 9748763073 For Genuine Sex Service At Just...
Vip profile Call Girls In Lonavala 9748763073 For Genuine Sex Service At Just...Vip profile Call Girls In Lonavala 9748763073 For Genuine Sex Service At Just...
Vip profile Call Girls In Lonavala 9748763073 For Genuine Sex Service At Just...
 
Connaught Place, Delhi Call girls :8448380779 Model Escorts | 100% verified
Connaught Place, Delhi Call girls :8448380779 Model Escorts | 100% verifiedConnaught Place, Delhi Call girls :8448380779 Model Escorts | 100% verified
Connaught Place, Delhi Call girls :8448380779 Model Escorts | 100% verified
 
Justdial Call Girls In Indirapuram, Ghaziabad, 8800357707 Escorts Service
Justdial Call Girls In Indirapuram, Ghaziabad, 8800357707 Escorts ServiceJustdial Call Girls In Indirapuram, Ghaziabad, 8800357707 Escorts Service
Justdial Call Girls In Indirapuram, Ghaziabad, 8800357707 Escorts Service
 
Pulmonary drug delivery system M.pharm -2nd sem P'ceutics
Pulmonary drug delivery system M.pharm -2nd sem P'ceuticsPulmonary drug delivery system M.pharm -2nd sem P'ceutics
Pulmonary drug delivery system M.pharm -2nd sem P'ceutics
 
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdfPests of cotton_Sucking_Pests_Dr.UPR.pdf
Pests of cotton_Sucking_Pests_Dr.UPR.pdf
 
Formation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disksFormation of low mass protostars and their circumstellar disks
Formation of low mass protostars and their circumstellar disks
 
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune WaterworldsBiogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
Biogenic Sulfur Gases as Biosignatures on Temperate Sub-Neptune Waterworlds
 
COST ESTIMATION FOR A RESEARCH PROJECT.pptx
COST ESTIMATION FOR A RESEARCH PROJECT.pptxCOST ESTIMATION FOR A RESEARCH PROJECT.pptx
COST ESTIMATION FOR A RESEARCH PROJECT.pptx
 
CELL -Structural and Functional unit of life.pdf
CELL -Structural and Functional unit of life.pdfCELL -Structural and Functional unit of life.pdf
CELL -Structural and Functional unit of life.pdf
 
Call Girls Alandi Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Alandi Call Me 7737669865 Budget Friendly No Advance BookingCall Girls Alandi Call Me 7737669865 Budget Friendly No Advance Booking
Call Girls Alandi Call Me 7737669865 Budget Friendly No Advance Booking
 
Seismic Method Estimate velocity from seismic data.pptx
Seismic Method Estimate velocity from seismic  data.pptxSeismic Method Estimate velocity from seismic  data.pptx
Seismic Method Estimate velocity from seismic data.pptx
 
dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...
dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...
dkNET Webinar "Texera: A Scalable Cloud Computing Platform for Sharing Data a...
 
Conjugation, transduction and transformation
Conjugation, transduction and transformationConjugation, transduction and transformation
Conjugation, transduction and transformation
 
Module for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learningModule for Grade 9 for Asynchronous/Distance learning
Module for Grade 9 for Asynchronous/Distance learning
 
Unit5-Cloud.pptx for lpu course cse121 o
Unit5-Cloud.pptx for lpu course cse121 oUnit5-Cloud.pptx for lpu course cse121 o
Unit5-Cloud.pptx for lpu course cse121 o
 
Kochi ❤CALL GIRL 84099*07087 ❤CALL GIRLS IN Kochi ESCORT SERVICE❤CALL GIRL
Kochi ❤CALL GIRL 84099*07087 ❤CALL GIRLS IN Kochi ESCORT SERVICE❤CALL GIRLKochi ❤CALL GIRL 84099*07087 ❤CALL GIRLS IN Kochi ESCORT SERVICE❤CALL GIRL
Kochi ❤CALL GIRL 84099*07087 ❤CALL GIRLS IN Kochi ESCORT SERVICE❤CALL GIRL
 
STS-UNIT 4 CLIMATE CHANGE POWERPOINT PRESENTATION
STS-UNIT 4 CLIMATE CHANGE POWERPOINT PRESENTATIONSTS-UNIT 4 CLIMATE CHANGE POWERPOINT PRESENTATION
STS-UNIT 4 CLIMATE CHANGE POWERPOINT PRESENTATION
 
Proteomics: types, protein profiling steps etc.
Proteomics: types, protein profiling steps etc.Proteomics: types, protein profiling steps etc.
Proteomics: types, protein profiling steps etc.
 

DNA Vaccines

  • 1. BY- AAYUSHI RAMBIA M.Sc. SEM I REG NO. 18308001 PONDICHERRY UNIVERSITY
  • 2.  A vaccine is a biological preparation that improves immunity to a particular disease. A vaccine typically contains an agent that resembles a disease-causing microorganism, and is often made from weakened or killed forms of the microbe, its toxins or one of its surface proteins. The agent stimulates the body's immune system to recognize the agent as foreign, destroy it, and "remember" it, so that the immune system can more easily recognize and destroy any of these microorganisms that it later encounters. (Definition as adopted from WHO)
  • 3. 1796 • British physician , Edward Jenner used the cowpox virus (vaccinia) to confer protection against smallpox, a related virus, in humans. 1870 1885 • Louis Pasteur created the first live attenuated bacterial vaccine against chicken cholera. • He created the first live attenuated viral vaccine against rabies. 1890- 1904 • Von Behring and Kitasato Shibasaburo successfully tested vaccines for diphtheria and tetanus 1914 • Tetanus vaccine becomes available. 1920- 1940 • Vaccines against tuberculosis , diphtheria and yellow fever , influenza and whooping cough created. 1955- 1960 • Salk and Sabin created two different types of vaccines against polio myelitis.
  • 4. (Adapted from Nature Reviews Microbiology volume9, pages889–893 (2011)
  • 5.  Recombinant DNA vaccines or simply DNA vaccines are plasmid containing the DNA sequence encoding the antigen(s) against which an immune response is sought, and relies on the in situ production of the target antigen.  Upon the injection of the DNA vaccines , the DNA is taken up by the cells and the encoded protein antigen is expressed , leading to both a humoral anitbody response and a cell mediated immune response.  These belong to the third generation of vaccines .  The use of DNA as a vaccine started with the work of Jon Wolff who injected DNA plasmids to produce a protein response in mice.
  • 7.  DNA vaccines are composed of bacterial plasmids.  Expression plasmids used in DNA-based vaccination normally contain two units: 1) The antigen expression unit composed of promoter/enhancer sequences, followed by antigen- encoding and polyadenylation sequences and 2) the production unit composed of bacterial sequences necessary for plasmid amplification and selection .  The construction of bacterial plasmids with vaccine inserts is accomplished using recombinant DNA technology.
  • 8.  Once constructed, the vaccine plasmid is transformed into bacteria, where bacterial growth produces multiple plasmid copies.  The plasmid DNA is then purified from the bacteria, by separating the circular plasmid from the much larger bacterial DNA and other bacterial impurities.  This purified DNA acts as the vaccine.
  • 11.  The major approaches involved in administration of DNA vaccines are :- 1) Injection of DNA vaccine in saline, using a standard hypodermic needle. Injection in saline is normally conducted intramuscularly (IM) in skeletal muscle, or intradermally (ID), delivering DNA to extracellular spaces. This can be assisted by electroporation by temporarily damaging muscle fibres with myotoxins such as bupivacaine; or by using hypertonic solutions of saline or sucrose. Through this method large amounts of DNA approximately 100-200 µg can be delivered .
  • 12. 2) Gene gun method involves the injection of plasmid DNA (pDNA) that has been adsorbed onto gold or tungsten micro particles into the target cells using compressed helium as an accelerant. Usually administered to ED (abdominal skin) , vaginal mucosa or surgically exposed muscle and other organs. Through this method small amounts of DNA approximately 16 ng can be delivered. The method sometimes causes burning sensation and in order to avoid this nowadays low pressure gene guns are used instead of gold coated DNA vaccines.
  • 13. 3) Another method includes the administration through pneumatic jet injections ED (abdominal skin). It helps deliver large amounts approximately 300 µg . 4) Aerosol instillation of naked DNA on mucosal surfaces, such as the nasal and lung mucosa and topical administration of pDNA to the eye. It helps deliver small amounts of DNA approximately upto 100 µg.
  • 14.  By two major pathways :- 1)Endogenous Antigenic Protein is presented by cell in which it is produced Antigenic Protein Antigenic Peptides Plasmid DNA Nucleus mRNA MHC-I
  • 15. Helper T-cell Memory T- cells Plasma T-cell
  • 16. 2) Exogenous Antigenic Protein is formed in one cell but presented by different cell. Antigenic Protein come outside
  • 17. Antigen Presenting Cell Antigenic Peptides T- Helper Cell Cytokines Activated B-Cell Memory B-Cell Plasma B-Cell Memory Antibodies MHC-II
  • 18.  Vaccination with no risk for infection.  Antigen presentation by both MHC class I and class II molecules.  Immune response focused only on antigen of interest.  Stability of vaccine for storage and shipping  Cost-effectiveness.  Long-term persistence of immunogen ADVANTAGES OF DNA VACCINES
  • 19.  Limited to protein immunogens  Risk of affecting genes controlling cell growth  Possibility of inducing antibody production against DNA  Possibility of tolerance to the antigen (protein) produced  Plasmid used is resistance to antibiotics for selection. It may raise the resistance to same antibiotic in the host  Over – expression may cause acute inflamatory response.
  • 20. There are currently 43 clinical trials evaluating DNA vaccines for viral and non-viral diseases listed in the clinicaltrials.gov database. The majority (62%) of these trials are investigating vaccines for HIV (33%) or cancers (29%). Almost half (38%) of cancer vaccines currently being investigated are targeting melanoma. The remaining 38% of enrolling or active clinical trials are investigating vaccines for influenza, hepatitis B and C, HPV, and malaria.
  • 21. From: Clinical Applications of DNA Vaccines: Current Progress . Published by Oxford University Press on behalf of the Infectious Diseases Society of America
  • 22.  With the advent of DNA vaccines there came a possibility for treatment of incurable diseases such HIV ,Hepatitis and Cancer.  Despite remarkable progress in the field of DNA vaccine research since its discovery in the early 1990s, the formal acceptance of this novel technology as a new modality of human vaccines depends on the successful demonstration of its safety and efficacy in advanced clinical trials.  Although clinical trials conducted so far have provided overwhelming evidence that DNA vaccines are well tolerated and have an excellent safety profile, the early designs of DNA vaccines failed to demonstrate sufficient immunogenicity in humans. However, studies conducted over the last few years have led to promising results, particularly when DNA vaccines were used in combination with other forms of vaccines.
  • 23.  Immunology by Kuby 4th Edition  Immunology by Kuby 6th Edition  Tang DC, DeVit M, Johnston SA. (1992)“Genetic immunization is a simple method for eliciting an immune response”. Nature; 356:152-4  https://www.tandfonline.com/doi/full/10.1586/14760584.7. 2.175  Clinical Infectious Diseases, Volume 53, Issue 3, 1 August 2011, Pages 296– 302,https://doi.org/10.1093/cid/cir334  www.nptel.com  https://www.nature.com/articles/nrg2432  https://www.nature.com/articles/gt201467  Google images